SSL Secured
All Major Cards Accepted
Apple Pay & Google Pay
2-Day Shipping Available
Intellectual Property · Clinical Evidence · Data Sources
Sources & Patents
Every claim VyVa makes about its products is sourced. This page documents — without omission — all patents, patent applications, and research citations behind each ingredient in the VyVa line. Status is stated accurately: granted patents are identified as such; applications in progress are clearly labelled as pending.
Last verified: May 2026 · Source documents on file: GRAS letters, COAs, patent filings, supplier technical reports, published research citations.
4Granted US Patents
1EU Patent Granted
3Pending Applications
4Peer-reviewed RCTs
10+Research Documents
How to Read This Page
Evidence tier classification
All research citations are classified by evidence tier — the same framework used internally to determine what can be claimed in ads, on PDPs, and on science pages.
A1
Peer-reviewed RCTRandomized controlled trial on humans. Highest tier. Approvable for all marketing channels with proper citation.
A2
Peer-reviewed human / mechanisticPublished human pharmacokinetics, safety, or hypothesis paper. Approvable with qualifiers.
B1
Observational studyPublished human observational research. Website science page only, with association disclaimer.
C
Manufacturer dataSupplier-conducted lab research, clinical evaluations, or case studies. Labelled ‘manufacturer data on file’ — never ‘clinical proof.’
Joint Cellular Support Gummies
Vflex — Q-Actin®
1 US Patent Granted4 Research Documents
✓ Granted Patents
US 9,326,977 B2
Iminosugar Compositions and Methods of Treating Inflammatory Disease
Holder: PhytoQuest Limited · Jurisdiction: United States
Scope: Composition and method-of-use patent covering idoBR1 iminosugar amino acid derived from cucumber (Cucumis sativus) for the treatment of inflammatory conditions.
Core composition and method patent. US market protection confirmed.
Research & Citation Record
Peer-reviewed RCT (A1)Nash et al. 2018 · PMC6207263Randomized, double-blind, placebo-controlled, 180-day, 3-arm trial (n=122)
Peer-reviewed RCT (A1)
Nash et al. 2018 · PMC6207263
Randomized, double-blind, placebo-controlled, 180-day, 3-arm trial (n=122)
Key finding: 70.3% WOMAC pain reduction at 20 mg/day; glucosamine-chondroitin arm 33.7%.
View published source →Peer-reviewed RCT (A1)Hausenblas et al. 2025 · Cureus 17(9):e93507 · NCT06246383Randomized, double-blind, placebo-controlled, 60-day trial (n=80)
Peer-reviewed RCT (A1)
Hausenblas et al. 2025 · Cureus 17(9):e93507 · NCT06246383
Randomized, double-blind, placebo-controlled, 60-day trial (n=80)
Key finding: 31.79% WOMAC improvement from baseline at Day 60; placebo declined 14.30%.
View published source →Peer-reviewed RCT (A1)Lloyd et al. 2025 · Frontiers in Nutrition · PubMed 40421033 · NCT05878847Randomized, placebo-controlled, 12-week trial (n=47, ages 50–78)
Peer-reviewed RCT (A1)
Lloyd et al. 2025 · Frontiers in Nutrition · PubMed 40421033 · NCT05878847
Randomized, placebo-controlled, 12-week trial (n=47, ages 50–78)
Key finding: Significant signal on finger dexterity (Nine-Hole Peg Test, p=0.011); elevated urinary melatonin metabolites; PSQI sleep trend non-significant.
View published source →Safety / Toxicology (A2)Kothari et al. 2018 · Toxicology Reports · PMC622432890-day animal toxicology study
Safety / Toxicology (A2)
Kothari et al. 2018 · Toxicology Reports · PMC6224328
90-day animal toxicology study
Key finding: NOAEL ≥1,000 mg/day — safety margin vs the 20 mg clinical dose is >50×. No genotoxicity. No adverse events. Well tolerated.
View published source →Cellular Glow & Renewal Gummies
Vioni+ — Ioniplex®
2 US Patents Granted1 Application Pending4 Research Documents
✓ Granted Patents
US 8,709,497
Mineral, Cosmetic, Pharmaceutical & Agricultural Compositions
Holder: Mineral BioSciences® · Jurisdiction: United States
Scope: Composition and method patent covering the Ioniplex® fulvic ionic mineral complex and its application across health, cosmetic, pharmaceutical, and agricultural uses — including enhanced cellular mineral delivery.
Core composition and delivery patent. The foundational IP for Ioniplex® as a cellular delivery vehicle.
US 8,927,031
Anti-Glycation Methods and Compositions
Holder: Mineral BioSciences® · Jurisdiction: United States
Scope: Method and composition patent specifically covering the use of Ioniplex® to inhibit glycation — the binding of sugars to proteins and lipids forming AGEs (Advanced Glycation End-products).
Unique among fulvic acid / shilajit-derived ingredients. No competitor holds this patent.
⏳ Patent Applications — Pending
US Application (filed 2016)
Methods and Compositions for Modulating Muscle and Bone Loss
Holder: Mineral BioSciences® · Jurisdiction: United States
Scope: Patent application covering Ioniplex® for the modulation of muscle and bone loss pathways — relevant to sports nutrition and active-adult applications.
Application filed 2016. Status as of May 2026: pending. Cannot be described as ‘patented’ until granted.
Research & Citation Record
Manufacturer-sponsored clinical evaluation (Tier C)Boisits 2009 · Study No. 3411BK0609 · International Research Services Inc., Port Chester NY6-week randomized double-blind placebo-controlled evaluation — nail condition
Manufacturer-sponsored clinical evaluation (Tier C)
Boisits 2009 · Study No. 3411BK0609 · International Research Services Inc., Port Chester NY
6-week randomized double-blind placebo-controlled evaluation — nail condition
Key finding: Improvements in nail condition parameters including nail growth velocity and nail strength metrics. Manufacturer data on file.
Source document on file. Not yet publicly linked.
Manufacturer laboratory data (Tier C)Sunny Biodiscovery Report 697-BIOAV (2015) · Santa Paula CA · In vitroIn vitro bioavailability in human dermal fibroblast cell culture
Manufacturer laboratory data (Tier C)
Sunny Biodiscovery Report 697-BIOAV (2015) · Santa Paula CA · In vitro
In vitro bioavailability in human dermal fibroblast cell culture
Key finding: Enhanced intracellular mineral delivery from Ioniplex® compared to free-mineral controls in human dermal fibroblast models.
Source document on file. Not yet publicly linked.
Manufacturer laboratory data (Tier C)Mineral BioSciences Reports 439, 466A (2006/2011) · ~20,000-gene microarrayIn vitro gene expression / MTT assay — mitochondrial metabolism; muscle & bone cell comparison
Manufacturer laboratory data (Tier C)
Mineral BioSciences Reports 439, 466A (2006/2011) · ~20,000-gene microarray
In vitro gene expression / MTT assay — mitochondrial metabolism; muscle & bone cell comparison
Key finding: Stimulation of mitochondrial metabolic pathway activity described; increased metabolic activity in human skeletal muscle and bone cell models when Ioniplex® added to commercial nutritional formulations.
Source document on file. Not yet publicly linked.
Manufacturer laboratory data (Tier C)Mineral BioSciences Reports 400, 3411BK0609 · In vitro fibroblast collagen assayIn vitro Type I collagen synthesis assay — human dermal fibroblasts
Manufacturer laboratory data (Tier C)
Mineral BioSciences Reports 400, 3411BK0609 · In vitro fibroblast collagen assay
In vitro Type I collagen synthesis assay — human dermal fibroblasts
Key finding: Effect on Type I collagen secretion by human dermal fibroblasts. Manufacturer data on file.
Source document on file. Not yet publicly linked.
Cellular Energy & Longevity Gummies
MitoV+ — MitoPrime®
2 Applications Pending3 Research Documents
⏳ Patent Applications — Pending
PCT/CN2019/121260
EAN B Manufacturing Technology — L-ergothioneine Production Process
Holder: NNB Nutrition · Jurisdiction: PCT (International Application)
Scope: PCT application covering NNB’s proprietary fermentation-based manufacturing process for L-ergothioneine (the EAN B process). This is a process patent application — it covers how MitoPrime® is made, not the molecule itself.
Filed November 2019. L-ergothioneine as a molecule is not patentable (naturally occurring). The process is what’s protected.
USPTO 63/138,804
Methods for Ameliorating Aging — Provisional Application
Holder: NNB Nutrition · Jurisdiction: United States (Provisional)
Scope: US provisional patent application covering methods of using L-ergothioneine for aging-related applications. Filed January 2021.
Provisional applications establish a priority date but do not grant patent rights. Current status of non-provisional filing not yet confirmed.
Research & Citation Record
Scientific hypothesis / perspective (A2)Ames 2018 · Proceedings of the National Academy of SciencesScientific opinion & review by Bruce N. Ames, PhD (UC Berkeley)
Scientific hypothesis / perspective (A2)
Ames 2018 · Proceedings of the National Academy of Sciences
Scientific opinion & review by Bruce N. Ames, PhD (UC Berkeley)
Key finding: Proposed L-ergothioneine as a ‘putative longevity-vitamin candidate’ based on its dedicated human transporter (OCTN1), tissue distribution, and association with aging biology. The ‘longevity vitamin’ designation requires the qualifier ‘putative’ or ‘proposed’ in all consumer copy.
Source document on file.
Human pharmacokinetics (A2)Cheah et al. 2017 · Peer-reviewed pharmacokinetics studyHuman pharmacokinetics study — oral ergothioneine
Human pharmacokinetics (A2)
Cheah et al. 2017 · Peer-reviewed pharmacokinetics study
Human pharmacokinetics study — oral ergothioneine
Key finding: Rapid intestinal absorption, low urinary loss, long tissue retention — confirmed the OCTN1 transporter mechanism and preferential accumulation in high-oxidative-stress tissues.
Source document on file.
Human observational (B1 — science page only)Smith et al. 2020 · Malmö Diet and Cancer Study (21-year cohort)21-year prospective observational study
Human observational (B1 — science page only)
Smith et al. 2020 · Malmö Diet and Cancer Study (21-year cohort)
21-year prospective observational study
Key finding: Higher plasma ergothioneine associated with reduced cardiovascular mortality (HR 0.79). ASSOCIATION only — does not prove supplementation reduces cardiovascular risk. Permitted on science page only with association disclaimer. Never in ads.
Source document on file.
Barrier Restoration Serum
Cellular Renewal — PhytoCellTec™ Malus Domestica
3 Patents Granted (2 US, 1 EU)1 No Patent — Confirmed1 Research Document
✓ Granted Patents
US 9,155,916 B2
Cosmetic or Dermatological Preparations Comprising Plant Cell Culture Extracts
Holder: Mibelle Biochemistry · Jurisdiction: United States
Scope: US patent covering cosmetic and dermatological preparations comprising PhytoCellTec™ plant stem cell culture extracts from Uttwiler Spätlauber apple.
Verified on USPTO and Mibelle’s own product pages. The definitive US grant.
US 8,580,320 B2
Plant Cell Culture Extract Cosmetic Compositions
Holder: Mibelle Biochemistry · Jurisdiction: United States
Scope: Earlier US patent in the PhytoCellTec™ family covering plant cell culture extract compositions for cosmetic use.
Confirmed granted. Part of Mibelle’s multi-jurisdiction patent family.
EP 1,985,280 B1
PhytoCellTec™ Malus Domestica — European Patent
Holder: Mibelle Biochemistry · Jurisdiction: European Patent Office
Scope: European equivalent covering the same plant cell culture extract technology.
Granted and in force.
✕ No Patent — Verified
Salmon-derived DNA polynucleotides (PDRN complex)
Not PatentedThe polynucleotide complex used in Cellular Renewal is pharmaceutical-grade material; no VyVa-owned or supplier-owned patent has been verified for this specific topical cosmetic application at the concentrations used in the finished serum. The PDRN/polynucleotide mechanism is well-described in the medical literature. Not currently marketed as ‘patented’ by VyVa.
Research & Citation Record
Supplier in-vivo study (Tier C)Schmid et al. 2008 · SOFW Journal (trade) — Mibelle supplier datan=20 volunteers, 28-day twice-daily 2% PhytoCellTec™ cream · PRIMOS wrinkle imaging
Supplier in-vivo study (Tier C)
Schmid et al. 2008 · SOFW Journal (trade) — Mibelle supplier data
n=20 volunteers, 28-day twice-daily 2% PhytoCellTec™ cream · PRIMOS wrinkle imaging
Key finding: 8% wrinkle depth reduction at 2 weeks; 15% at 4 weeks. Supplier-conducted, trade journal — not a peer-reviewed RCT.
Source document on file.
Night Renewal Serum
Cellular Radiance — NovoRetin™
No Patent — Confirmed2 Research Documents
✕ No Patent — Verified
NovoRetin™
Not PatentedNo Mibelle-owned patent has been located for NovoRetin™ on USPTO, EPO (Espacenet), Google Patents, or WIPO as of May 2026. Mibelle’s own product page lists COSMOS and NATRUE certifications only — unlike PhytoCellTec™, which explicitly lists patent numbers. The CYP26A1-inhibitor patents that exist (US 7,468,391; US 10,874,634; US 11,795,148) are owned by pharmaceutical companies covering synthetic molecules. The word ‘Patented’ must not be used for NovoRetin™ in any VyVa marketing.
Research & Citation Record
Supplier in-vivo study (Tier C)Mibelle anti-aging study (supplier dossier)Placebo-controlled, n=18 women aged 42–70, 28-day twice-daily
Supplier in-vivo study (Tier C)
Mibelle anti-aging study (supplier dossier)
Placebo-controlled, n=18 women aged 42–70, 28-day twice-daily
Key finding: Supplier-reported: +20% skin elasticity, +14% skin density. Small sample, supplier-conducted, not registered on ClinicalTrials.gov, not published in a peer-reviewed dermatology journal.
Source document on file.
Supplier in-vivo study (Tier C)Mibelle acne study — HPC Today 5/2025 (trade magazine)Double-blind, placebo-controlled, n=44 Asian women aged 30–52, 28 days
Supplier in-vivo study (Tier C)
Mibelle acne study — HPC Today 5/2025 (trade magazine)
Double-blind, placebo-controlled, n=44 Asian women aged 30–52, 28 days
Key finding: Reduction in comedone counts. Trade-journal publication — not a peer-reviewed clinical trial.
Source document on file.
Brightening Barrier Serum
Cellular Clarity — Delentigo™
No Patent — Confirmed1 Research Document
✕ No Patent — Verified
Delentigo™
Not PatentedNo Mibelle-owned patent has been located for Delentigo™ on USPTO, EPO, Google Patents, or WIPO as of May 2026. A third-party patent (EP3791932A1) explicitly treats Delentigo™ as a purchased commercial input — confirming it is not proprietary to Mibelle from an IP standpoint. The word ‘Patented’ must not be used for Delentigo™ in any VyVa marketing.
Research & Citation Record
Supplier in-vivo study (Tier C)Mibelle Delentigo supplier study (2015 dossier)n=12 Caucasian volunteers, ages 40–66, 4% Delentigo™ cream twice daily, 8 weeks (hands)
Supplier in-vivo study (Tier C)
Mibelle Delentigo supplier study (2015 dossier)
n=12 Caucasian volunteers, ages 40–66, 4% Delentigo™ cream twice daily, 8 weeks (hands)
Key finding: Reduction in spot-vs-normal skin colorimetry contrast (SPA99, Courage & Khazaka). n=12 is below standard dermatology RCT thresholds. Not registered on ClinicalTrials.gov. Not peer-reviewed.
Source document on file.
Complete Reference Index
All citations — every product
Every research document referenced across VyVa’s product line, in one place, with tier classification and sourcing notes.
| Reference | Product | Evidence Tier | Key Finding | Source |
|---|---|---|---|---|
| Nash 2018 | Vflex (Q-Actin®) | A1 — Peer-reviewed RCT | 180-day, 3-arm RCT (n=122). 70.3% WOMAC reduction at 20 mg/day vs 33.7% for glucosamine-chondroitin 2,700 mg/day. | PubMed → |
| Hausenblas 2025 | Vflex (Q-Actin®) | A1 — Peer-reviewed RCT | 60-day RCT (n=80). 31.79% WOMAC improvement at Day 60. Significant vs placebo (declined 14.30%). | DOI → |
| Lloyd 2025 | Vflex (Q-Actin®) | A1 — Peer-reviewed RCT | 12-week RCT (n=47, 50–78). Significant finger dexterity signal (p=0.011). Urinary melatonin metabolites elevated. PSQI sleep trend non-significant. | PubMed → |
| Kothari 2018 | Vflex (Q-Actin®) | A2 — Safety / Toxicology | NOAEL ≥1,000 mg/kg/day over 90 days. No genotoxicity. Safety margin >50× vs 20 mg clinical dose. | PubMed → |
| Boisits 2009 | Vioni+ (Ioniplex®) | C — Manufacturer clinical eval | 6-week double-blind placebo-controlled evaluation. Nail growth and nail condition parameters showed measurable improvement. Manufacturer-sponsored. | On file |
| Report 697-BIOAV | Vioni+ (Ioniplex®) | C — Manufacturer lab data | In vitro human dermal fibroblast model. Enhanced intracellular mineral delivery vs free-mineral controls. | On file |
| Reports 439, 466A | Vioni+ (Ioniplex®) | C — Manufacturer lab data | ~20,000-gene microarray. Mitochondrial metabolism stimulation in human cell culture. Muscle and bone cell metabolic activity. | On file |
| Reports 400, 3411BK0609 | Vioni+ (Ioniplex®) | C — Manufacturer lab data | In vitro fibroblast collagen secretion assay. Support for Type I collagen synthesis pathway. | On file |
| Ames 2018 | MitoV+ (MitoPrime®) | A2 — Hypothesis / perspective | Proposed L-ergothioneine as a ‘putative longevity-vitamin candidate’. Requires ‘putative’ qualifier in all consumer copy. | On file |
| Cheah 2017 | MitoV+ (MitoPrime®) | A2 — Human pharmacokinetics | Rapid intestinal absorption. Low urinary loss. Long tissue retention via OCTN1. High accumulation in brain, liver, skin, mitochondria. | On file |
| Smith 2020 (Malmö) | MitoV+ (MitoPrime®) | B1 — Observational (science page only) | Higher plasma ergothioneine associated with HR 0.79 cardiovascular mortality. ASSOCIATION ONLY — cannot claim supplementation reduces cardiovascular risk. | On file |
| Schmid 2008 | Cellular Renewal (PhytoCellTec™) | C — Supplier in-vivo study | n=20, 28-day 2% PhytoCellTec™ cream. 8% wrinkle depth reduction at 2 weeks; 15% at 4 weeks. Trade journal. | On file |
| NovoRetin 2022 | Cellular Radiance (NovoRetin™) | C — Supplier in-vivo study | n=18, 28-day. +20% skin elasticity, +14% skin density (supplier-reported). Not peer-reviewed, not registered. | On file |
| Delentigo 2015 | Cellular Clarity (Delentigo™) | C — Supplier in-vivo study | n=12, 8-week, 4% Delentigo™ on hands. Colorimetry (SPA99). Sub-clinical sample size. Not peer-reviewed. | On file |
Compliance Notes — What This Page Confirms
What is patented. What is pending. What is not.
Patents Confirmed Granted
US 9,326,977 B2 — Q-Actin® (Vflex)
US 8,709,497 — Ioniplex® (Vioni+)
US 8,927,031 — Ioniplex® Anti-Glycation (Vioni+)
US 9,155,916 B2 — PhytoCellTec™ (Cellular Renewal)
US 8,580,320 B2 — PhytoCellTec™ (Cellular Renewal)
EP 1,985,280 B1 — PhytoCellTec™ EU (Cellular Renewal)
Applications Pending — Not Yet Granted
US Application (2016) — Ioniplex® Muscle & Bone (Vioni+)
PCT/CN2019/121260 — MitoPrime® Manufacturing Process (MitoV+)
USPTO 63/138,804 Provisional — MitoPrime® Aging Methods (MitoV+)
No Patent — Confirmed
NovoRetin™ — No Mibelle-owned patent located (Cellular Radiance)
Delentigo™ — No Mibelle-owned patent located (Cellular Clarity)
Salmon-derived DNA polynucleotides — No VyVa-specific patent (Cellular Renewal)
Key Research on File (Highest Tier)
Nash 2018 — A1 RCT, 180-day (Vflex / Q-Actin®)
Hausenblas 2025 — A1 RCT, 60-day (Vflex / Q-Actin®)
Lloyd 2025 — A1 RCT, 12-week (Vflex / Q-Actin®)
Kothari 2018 — A2 Safety study (Vflex / Q-Actin®)
Ames 2018 PNAS — A2 Hypothesis (MitoV+ / MitoPrime®)
Our Position
Why we publish this
Most supplement brands bury their sources in footnotes or cite them without links. VyVa publishes a dedicated patents and sources page because the quality of our ingredients is the product — and you should be able to verify every claim we make.
Manufacturer laboratory data is labelled as such. Peer-reviewed RCTs are cited with PMC and DOI links. Patent applications that have not yet been granted are not called ‘patented.’ Ingredients without verifiable patents are listed honestly. This is the standard we hold ourselves to.
These statements have not been evaluated by the Food and Drug Administration. VyVa dietary supplement products are not intended to diagnose, treat, cure, or prevent any disease. VyVa skincare products are cosmetics and are not intended to diagnose, treat, cure, or prevent any medical or dermatological condition. Individual results may vary. Patent data verified to May 2026. Source documents on file at Vidiwell LLC, Wyoming.
